Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VIREX

Financiado

Cerrado

Mumps VIRus EXploitation of the human adhesion receptor GPR125

Mumps virus is a re-emerging pathogen that causes painful inflammatory symptoms, such as parotitis (salivary gland infection) and orchitis (testis infection). It is highly neurotropic with evidence of brain infection in half of ca... ver más

30/06/2022

UCPH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-06-30

ERC-CoG-2015: ERC Consolidator Grant Scope:Objectives

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UCPH

1.81M€ | Lider

IBERICOS DE ARAUZO 2004

538.86K€ | Participante

Proyectos interesantes

BRACE

Medical Technol...

Applied Physics

166K€ Cerrado

NEF-PATHOGENESIS

Medical Technol...

Applied Physics

260K€ Cerrado

PID2020-115476RB-I00

Medical Technol...

Applied Physics

303K€ Cerrado

ARENAVIRUS

Medical Technol...

Applied Physics

183K€ Cerrado

SAF2012-38368

Medical Technol...

Data Science

49K€ Cerrado

Bat Flu

Medical Technol...

Applied Physics

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 72 meses Fecha Inicio: 2016-06-09
Fecha Fin: 2022-06-30

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Mumps virus is a re-emerging pathogen that causes painful inflammatory symptoms, such as parotitis (salivary gland infection) and orchitis (testis infection). It is highly neurotropic with evidence of brain infection in half of cases and clinical evidence in up to 10%. It is a small RNA virus belonging to the family of paramyxoviridae that includes e.g. viruses for measles and pneumonia, all having a huge impact on global economics and human health. Current vaccine programs have not managed to eliminate mumps and infections occur also in vaccinated individuals. Seven transmembrane (7TM) receptors are important drug targets. Large DNA viruses (herpes- and pox-) assign large parts of their genomes to exploit 7TM receptors. No such mechanism has however yet been described for small viruses. Based on strong preliminary data, I will in this interdisciplinary project test the groundbreaking hypothesis that the adhesion 7TM receptor GPR125 is central for the organ damage caused by mumps virus via an interaction with the mumps virus-encoded short-hydrophobic (SH)-protein. I will do so by determining: 1 - The functional consequences of GPR125-SH-interaction at a single cell, organ and whole body level within the context of mumps virus infection 2 - The structural requirements for the GPR125-mumps virus interaction using NMR and resolution of crystal structure in preparation for future drug design The project is high risk and high gain, yet the gain clearly exceeds the risk. On account of my past expertise in pharmacology and virology, and that of several expert collaborators, the project is indeed feasible. It has tremendous perspectives as SH-proteins are present also in other viruses. The SH-GPR125 complex might thus represent a general principle for organ damage and a mode of action more generally amenable to therapeutic interference. In fact, novel approaches, mechanism-based, might be seen as more appealing to those who fear current vaccination 'modes'.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores